The Tardive Dyskinesia Treatment Market is expected to register a CAGR of 4.2% during the forecast period.
COVID-19 has impacted the patient’s access to healthcare facilities as the pandemic has forced the patients to wait for life-saving diagnostics as well as treatment procedures. To slow the spread of the virus, many hospitals have reduced or postponed non-emergency services, like as screenings and diagnostic scans. According to the article published in Verywellhealth in October 2021, titled "What to Know About Tardive Dyskinesia and COVID-19," mental health disorders showed an association between the presence of any mental illness and an increased need for hospitalization or dying from COVID-19.
This is attributed to the growing number of Schizophrenia Patients and rising incidences of neurological disorders. With the long-term use of antipsychotic drugs by schizophrenia patients, the chances of patients suffering from tardive dyskinesia are high. Thus high risk is associated with a growing number of antipsychotic drugs leading to promoting the growth of the overall market. For instance, as per the World Health Organization Report in January 2022, Schizophrenia affects about 24 million individuals globally, or 0.32 %. Adults had a rate of 1 in 222 persons (0.45 %).
Furthermore, patients with Alzheimer's disease are more susceptible to tardive dyskinesia because the antipsychotic medication treatment and the rising prevalence of Alzheimer's disease anticipated the market growth. According to the Alzheimer Society of Canada 2021, over 500,000 Canadians are living with dementia. By 2030, this number is expected to rise to 912,000. Thus, rising in the prevalence of Alzheimer's disease is expected to rise in the pool population for tardive dyskinesia, thereby increasing the need for treatment, likely to boost the market.
Additionally, Also, the increasing prevalence of epilepsy in Mexico is also one of the factors driving the growth of the market studied. According to Anales Médicos de la Asociación Médica del Centro Médico ABC, in 2020, Epilepsy has a higher prevalence in developing countries and in Mexico. Prevalence of epilepsy in Mexico was reported with rates of 3.9 to 42.2 per 1,000 inhabitants. Thus increasing the prevalence of neurological diseases tardive dyskinesia population is expected to increase, thereby boosting the market studied.
However, side effects of drugs lack awareness about the disorder, and many undiagnosed cases may restrain the market to a certain extent.
The vesicular monoamine transporter type 2 (VMAT2) inhibitors are agents that cause a depletion of neuroactive peptides such as dopamine in nerve terminals and are used to treat chorea due to neurodegenerative diseases (such as Huntington chorea) or dyskinesias due to neuroleptic medications (tardive dyskinesia).
VMAT is expected to witness healthy growth in the future attributed to a growing number of neurological disorders and growing antipsychotic prescriptions. According to a study titled “Parkinson’s disease in China: a forty-year growing track of bedside work” published in 2019, the health burden of Parkinson’s disease was found to be increasing rapidly in China. Tardive dyskinesia is associated with Parkinson's therapy, and it is expected that the prevalence of Parkinson's disease will rise over the forecast period, resulting in increased demand for the treatment option, boosting segment growth.
Several product approvals in VMAT inhibitors are promoting the growth of the market. For instance, Food and Drug Administration (FDA) for the drug Valbenazine marketed under Ingrezza Austedo and among others. This results in driving the Tardive dyskinesia Treatment market.
Several product approvals in VMAT inhibitors are promoting the growth of the market.
North America is expected to hold a significant market share in the global Tardive Dyskinesia Treatment Market due to the increasing aging population, high prevalence of schizophrenia, increasing awareness, increasing healthcare expenditure, and the presence of well-established healthcare infrastructure. As the growing aging population will be leading to many diseases related to neurological for which this population has to take antipsychiatric drugs. Thus these populations are more prone to develop these diseases. According to the National Alliance on Mental Health in May 2021, the prevalence of schizophrenia in the United states is in the range of 0.25% to 0.64%, or 1.5 million people per year.
Moreover, targeted patient pools such as populations treated with schizophrenia and bipolar disorder in this region are also associated with this disorder, hence promoting the growth of the tardive dyskinesia treatment market in this region.
The COVID-19 pandemic has affected the supply chain of pharmaceutical products. The restrictions on pharmaceutical manufacturing and export affected many products sold in some countries, such as the United States, Europe, and other countries. Some of the drugs are manufactured in-house at the pharma companies, while other drugs of the company are manufactured with facilities in other countries, such as contract manufacturing services, which further impacts the supply chain of products. Hence, the delayed supply of second-generation antipsychotics in pharmacies and other end-user settings caused by restriction or cancellation of the export of medicines has negatively impacted the market growth. However, restrictions on imports and export are now partially relieved, which further creates growth avenues in the forecasted period.
The Tardive Dyskinesia Treatment Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Teva Pharmaceutical Industries Ltd, Neurocrine Biosciences, Inc, Sun Pharmaceutical Industries Ltd, SteriMax Inc., Lannett Co Inc, Sanis, and Allergan.
This product will be delivered within 2 business days.
COVID-19 has impacted the patient’s access to healthcare facilities as the pandemic has forced the patients to wait for life-saving diagnostics as well as treatment procedures. To slow the spread of the virus, many hospitals have reduced or postponed non-emergency services, like as screenings and diagnostic scans. According to the article published in Verywellhealth in October 2021, titled "What to Know About Tardive Dyskinesia and COVID-19," mental health disorders showed an association between the presence of any mental illness and an increased need for hospitalization or dying from COVID-19.
This is attributed to the growing number of Schizophrenia Patients and rising incidences of neurological disorders. With the long-term use of antipsychotic drugs by schizophrenia patients, the chances of patients suffering from tardive dyskinesia are high. Thus high risk is associated with a growing number of antipsychotic drugs leading to promoting the growth of the overall market. For instance, as per the World Health Organization Report in January 2022, Schizophrenia affects about 24 million individuals globally, or 0.32 %. Adults had a rate of 1 in 222 persons (0.45 %).
Furthermore, patients with Alzheimer's disease are more susceptible to tardive dyskinesia because the antipsychotic medication treatment and the rising prevalence of Alzheimer's disease anticipated the market growth. According to the Alzheimer Society of Canada 2021, over 500,000 Canadians are living with dementia. By 2030, this number is expected to rise to 912,000. Thus, rising in the prevalence of Alzheimer's disease is expected to rise in the pool population for tardive dyskinesia, thereby increasing the need for treatment, likely to boost the market.
Additionally, Also, the increasing prevalence of epilepsy in Mexico is also one of the factors driving the growth of the market studied. According to Anales Médicos de la Asociación Médica del Centro Médico ABC, in 2020, Epilepsy has a higher prevalence in developing countries and in Mexico. Prevalence of epilepsy in Mexico was reported with rates of 3.9 to 42.2 per 1,000 inhabitants. Thus increasing the prevalence of neurological diseases tardive dyskinesia population is expected to increase, thereby boosting the market studied.
However, side effects of drugs lack awareness about the disorder, and many undiagnosed cases may restrain the market to a certain extent.
Key Market Trends
VMAT Inhibitor is Expected to Witness a healthy Growth in Future
The vesicular monoamine transporter type 2 (VMAT2) inhibitors are agents that cause a depletion of neuroactive peptides such as dopamine in nerve terminals and are used to treat chorea due to neurodegenerative diseases (such as Huntington chorea) or dyskinesias due to neuroleptic medications (tardive dyskinesia).
VMAT is expected to witness healthy growth in the future attributed to a growing number of neurological disorders and growing antipsychotic prescriptions. According to a study titled “Parkinson’s disease in China: a forty-year growing track of bedside work” published in 2019, the health burden of Parkinson’s disease was found to be increasing rapidly in China. Tardive dyskinesia is associated with Parkinson's therapy, and it is expected that the prevalence of Parkinson's disease will rise over the forecast period, resulting in increased demand for the treatment option, boosting segment growth.
Several product approvals in VMAT inhibitors are promoting the growth of the market. For instance, Food and Drug Administration (FDA) for the drug Valbenazine marketed under Ingrezza Austedo and among others. This results in driving the Tardive dyskinesia Treatment market.
Several product approvals in VMAT inhibitors are promoting the growth of the market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant market share in the global Tardive Dyskinesia Treatment Market due to the increasing aging population, high prevalence of schizophrenia, increasing awareness, increasing healthcare expenditure, and the presence of well-established healthcare infrastructure. As the growing aging population will be leading to many diseases related to neurological for which this population has to take antipsychiatric drugs. Thus these populations are more prone to develop these diseases. According to the National Alliance on Mental Health in May 2021, the prevalence of schizophrenia in the United states is in the range of 0.25% to 0.64%, or 1.5 million people per year.
Moreover, targeted patient pools such as populations treated with schizophrenia and bipolar disorder in this region are also associated with this disorder, hence promoting the growth of the tardive dyskinesia treatment market in this region.
The COVID-19 pandemic has affected the supply chain of pharmaceutical products. The restrictions on pharmaceutical manufacturing and export affected many products sold in some countries, such as the United States, Europe, and other countries. Some of the drugs are manufactured in-house at the pharma companies, while other drugs of the company are manufactured with facilities in other countries, such as contract manufacturing services, which further impacts the supply chain of products. Hence, the delayed supply of second-generation antipsychotics in pharmacies and other end-user settings caused by restriction or cancellation of the export of medicines has negatively impacted the market growth. However, restrictions on imports and export are now partially relieved, which further creates growth avenues in the forecasted period.
Competitive Landscape
The Tardive Dyskinesia Treatment Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Teva Pharmaceutical Industries Ltd, Neurocrine Biosciences, Inc, Sun Pharmaceutical Industries Ltd, SteriMax Inc., Lannett Co Inc, Sanis, and Allergan.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Teva Pharmaceutical Industries Ltd
- Neurocrine Biosciences, Inc
- Sun Pharmaceutical Industries Ltd
- SteriMax Inc.
- Adamas Pharmaceuticals, Inc
- Sanis
- AbbVie Inc.
Methodology
LOADING...
